Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
29.02
-0.08 (-0.27%)
Jan 17, 2025, 4:00 PM EST - Market closed
Immunocore Holdings Revenue
Immunocore Holdings had revenue of $80.25M in the quarter ending September 30, 2024, with 23.74% growth. This brings the company's revenue in the last twelve months to $296.31M, up 25.09% year-over-year. In the year 2023, Immunocore Holdings had annual revenue of $249.43M with 43.05% growth.
Revenue (ttm)
$296.31M
Revenue Growth
+25.09%
P/S Ratio
4.88
Revenue / Employee
$596,201
Employees
497
Market Cap
1.45B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 249.43M | 75.07M | 43.05% |
Dec 31, 2022 | 174.36M | 137.88M | 377.91% |
Dec 31, 2021 | 36.48M | 6.37M | 21.15% |
Dec 31, 2020 | 30.11M | 4.45M | 17.32% |
Dec 31, 2019 | 25.67M | 2.02M | 8.52% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sep 30, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
IMCR News
- 10 days ago - Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 14 days ago - Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 18 days ago - Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development - GlobeNewsWire
- 4 weeks ago - Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME - GlobeNewsWire
- 7 weeks ago - Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma - GlobeNewsWire
- 2 months ago - Immunocore to present at upcoming investor conferences - GlobeNewsWire
- 2 months ago - Immunocore reports third quarter financial results and provides a business update - GlobeNewsWire
- 4 months ago - Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer - GlobeNewsWire